Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation

Journal of Leukocyte Biology

Volumn 87, Issue 2, 2010, Pages 345-354

  Lappas, Courtney M ^a   Liu, Po Ching ^b   Linden, Joel ^c   Kang, Elizabeth M ^b   Malech, Harry L ^b  

^a LEBANON VALLEY COLLEGE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Immunodeficiency; Inflammation; T lymphocytes

Indexed keywords

4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; CD40 LIGAND; CD69 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; CYTOKINE; LEUKOCYTE ANTIGEN; PURINE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LIVER; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; THERAPY DELAY; TREATMENT DURATION; UPREGULATION; WEIGHT REDUCTION; ACUTE DISEASE; ALLOTRANSPLANTATION; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; PATHOLOGY;

MURINAE; MUS;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOHEXANECARBOXYLIC ACIDS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MICE; PURINES; RECEPTOR, ADENOSINE A2A; TRANSPLANTATION, HOMOLOGOUS;

EID: 76149100209     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0609388     Document Type: Article

References (46)

1. Morris, E. S., Hill, G. R. (2007) Advances in the understanding of acute graft-versus-host disease. Br. J. Haematol. 137, 3-19.
2. Han, S. B., Lee, C. W., Yoon, Y. D., Kim, Y. K., Lee, K., Park, S. K., Kim, H. M. (2005) Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. Biochem. Pharmacol. 70, 1518-1526.
3. Furlong, T., Kiem, H. P., Appelbaum, F. R., Carpenter, P. A., Deeg, H. J., Doney, K., Flowers, M. E., Mielcarek, M., Nash, R. A., Storb, R., Martin, P. J. (2008) Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol. Blood Marrow Transplant. 14, 531-537.
4. Nash, R. A., Antin, J. H., Karanes, C., Fay, J. W., Avalos, B. R., Yeager, A. M., Przepiorka, D., Davies, S., Petersen, F. B., Bartels, P., Buell, D., Fitzsimmons, W., Anasetti, C., Storb, R., Ratanatharathorn, V. (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96, 2062-2068.
5. MacMillan, M. L., Weisdorf, D. J., Wagner, J. E., DeFor, T. E., Burns, L. J., Ramsay, N. K., Davies, S. M., Blazar, B. R. (2002) Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol. Blood Marrow Transplant. 8, 387-394.
6. Bacigalupo, A. (2007) Management of acute graft-versus-host disease. Br. J. Haematol. 137, 87-98.
7. Jacobsohn, D. A. (2002) Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin. Investig. Drugs 11, 1271-1280.
8. Jacobsohn, D. A. (2003) Emerging therapies for graft-versus-host disease. Expert Opin. Emerg. Drugs 8, 323-338.
9. Holler, E. (2007) Progress in acute graft versus host disease. Curr. Opin. Hematol. 14, 625-631.
10. Hashimoto, D., Asakura, S., Matsuoka, K., Sakoda, Y., Koyama, M., Aoyama, K., Tanimoto, M., Teshima, T. (2007) FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Eur. J. Immunol. 37, 271-281.
11. Trenado, A., Sudres, M., Tang, Q., Maury, S., Charlotte, F., Grégoire, S., Bonyhadi, M., Klatzmann, D., Salomon, B. L., Cohen, J. L. (2006) Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J. Immunol. 176, 1266-1273.
12. O'Shaughnessy, M. J., Chen, Z. M., Gramaglia, I., Taylor, P. A., Panoskaltsis-Mortari, A., Vogtenhuber, C., Palmer, E., Grader-Beck, T., Boussiotis, V. A., Blazar, B. R. (2007) Elevation of intracellular cyclic AMP in alloreactive CD4(+) T cells induces alloantigen-specific tolerance that can prevent GVHD lethality in vivo. Biol. Blood Marrow Transplant. 13, 530-542.
13. Lappas, C. M., Sullivan, G. W., Linden, J. (2005) Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin. Investig. Drugs 14, 797-806.
14. Awad, A. S., Huang, L., Ye, H., Duong, E. T., Bolton, W. K., Linden, J., Okusa, M. D. (2006) Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290, F828-F837.
15. Lappas, C. M., Day, Y. J., Marshall, M. A., Engelhard, V. H., Linden, J. (2006) Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. 203, 2639-2648.
16. Linden, J. (2005) Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. 67, 1385-1387.
17. Naganuma, M., Wiznerowicz, E. B., Lappas, C. M., Linden, J., Worthington, M. T., Ernst, P. B. (2006) Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol. 177, 2765-2769.
18. Odashima, M., Bamias, G., Rivera-Nieves, J., Linden, J., Nast, C. C., Moskaluk, C. A., Marini, M., Sugawara, K., Kozaiwa, K., Otaka, M., Watanabe, S., Cominelli, F. (2005) Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 129, 26-33.
19. Day, Y. J., Huang, L., McDuffie, M. J., Rosin, D. L., Ye, H., Chen, J. F., Schwarzschild, M. A., Fink, J. S., Linden, J., Okusa, M. D. (2003) Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest. 112, 883-891.
20. Yang, Z., Day, Y., Toufektsian, M. C., Xu, Y., Ramos, S. I., Marshall, M. A., French, B. A., Linden, J. (2006) Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 114, 2056-2064.
21. Odashima, M., Otaka, M., Jin, M., Horikawa, Y., Matsuhashi, T., Ohba, R., Linden, J., Watanabe, S. (2005) Selective adenosine A receptor agonist, ATL146e, attenuates stress-induced gastric lesions in rats. J. Gastroenterol. Hepatol. 20, 275-280.
22. Sullivan, G. W., Fang, G., Linden, J., Scheld, W. M. (2004) A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J. Infect. Dis. 189, 1897-1904.
23. Montesinos, M. C., Desai, A., Cronstein, B. N. (2006) Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res. Ther. 8, R53.
24. Montesinos, M. C., Yap, J. S., Desai, A., Posadas, I., McCrary, C. T., Cronstein, B. N. (2000) Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43, 656-663.
25. Zarek, P. E., Huang, C. T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., Powell, J. D. (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251-259.
26. Hakim, F. T., Sharrow, S. O., Payne, S., Shearer, G. M. (1991) Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes. J. Immunol. 146, 2108-2115.
27. Via, C. S., Finkelman, F. D. (1993) Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int. Immunol. 5, 565-572.
28. Via, C. S., Sharrow, S. O., Shearer, G. M. (1987) Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J. Immunol. 139, 1840-1849.
29. Beilhack, A., Schulz, S., Baker, J., Beilhack, G. F., Wieland, C. B., Herman, E. I., Baker, E. M., Cao, Y. A., Contag, C. H., Negrin, R. S. (2005) In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106, 1113-1122.
30. Mapara, M. Y., Leng, C., Kim, Y. M., Bronson, R., Lokshin, A., Luster, A., Sykes, M. (2006) Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol. Blood Marrow Transplant. 12, 623-634.
31. Piper, K. P., Horlock, C., Curnow, S. J., Arrazi, J., Nicholls, S., Mahendra, P., Craddock, C., Moss, P. A. (2007) CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 110, 3827-3832.
32. Merad, M., Hoffmann, P., Ranheim, E., Slaymaker, S., Manz, M. G., Lira, S. A., Charo, I., Cook, D. N., Weissman, I. L., Strober, S., Engleman, E. G. (2004) Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat. Med. 10, 510-517.
33. Beider, K., Nagler, A., Wald, O., Franitza, S., Dagan-Berger, M., Wald, H., Giladi, H., Brocke, S., Hanna, J., Mandelboim, O., Darash-Yahana, M., Galun, E., Peled, A. (2003) Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 102, 1951-1958.
34. Varona, R., Cadenas, V., Gomez, L., Martinez, A. C., Marquez, G. (2005) CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood 106, 18-26.
35. Fujii, N., Hiraki, A., Aoe, K., Murakami, T., Ikeda, K., Masuda, K., Matsuo, K., Shinagawa, K., Ishimaru, F., Sugi, K., Darzynkiewicz, Z., Tanimoto, M. (2006) Serum cytokine concentrations and acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation: concurrent measurement of ten cytokines and their respective ratios using cytometric bead array. Int. J. Mol. Med. 17, 881-885.
36. Ju, X. P., Xu, B., Xiao, Z. P., Li, J. Y., Chen, L., Lu, S. Q., Huang, Z. X. (2005) Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation. Bone Marrow Transplant. 35, 1179-1186.
37. Kim, S. S. (2007) Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. Ann. Pharmacother. 41, 1436-1444.
38. Lappas, C. M., Rieger, J. M., Linden, J. (2005) A2A adenosine receptor induction inhibits IFN-γ production in murine CD4+ T cells. J. Immunol. 174, 1073-1080.
39. Sullivan, G. W. (2003) Adenosine A2A receptor agonists as anti-inflammatory agents. Curr. Opin. Investig. Drugs 4, 1313-1319.
40. Butler, J. J., Mader, J. S., Watson, C. L., Zhang, H., Blay, J., Hoskin, D. W. (2003) Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways. J. Cell. Biochem. 89, 975-991.
41. Apasov, S. G., Sitkovsky, M. V. (1999) The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int. Immunol. 11, 179-189.
42. Jaksch, M., Mattsson, J. (2005) The pathophysiology of acute graft-versus-host disease. Scand. J. Immunol. 61, 398-409.
43. Ohta, A., Sitkovsky, M. (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916-920.
44. Panoskaltsis-Mortari, A., Price, A., Hermanson, J. R., Taras, E., Lees, C., Serody, J. S., Blazar, B. R. (2004) In vivo imaging of graft-versus-host- disease in mice. Blood 103, 3590-3598.
45. Van Lint, M. T., Milone, G., Leotta, S., Uderzo, C., Scimè, R., Dallorso, S., Locasciulli, A., Guidi, S., Mordini, N., Sica, S., Cudillo, L., Fagioli, F., Selleri, C., Bruno, B., Arcese, W., Bacigalupo, A. (2006) Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 107, 4177-4181.
46. Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K., Huang, X., Caldwell, S., Liu, K., Smith, P., Chen, J. F., Jackson, E. K., Apasov, S., Abrams, S., Sitkovsky, M. (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. USA 103, 13132-13137.